AllCourtTENNIS
Explorer
The Nature paper behind SYNCHRONIZE-MASLD
Across 48 weeks the trial recorded an average 12% reduction, with a specific improvement in liver fat. Around 20% of participants, though, stopped treatment because of gastrointestinal side effects.
Zealand shares have shed roughly 25%, and European markets are still open.
Across 48 weeks the trial recorded an average 12% reduction, with a specific improvement in liver fat. Around 20% of participants, though, stopped treatment because of gastrointestinal side effects.
Zealand shares have shed roughly 25%, and European markets are still open.
